Skip to main content

Table 1 Specificity spectrum of hematein.

From: Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library

Protein kinase Kinase activity (%) Protein kinase Kinase activity (%)
Abl 76 Lyn 111
CDK1 95 MAPK1 87
CDK2 113 MAPK2 74
CDK3 55 MKK6 99
CDK5 84 MSK1 91
CDK7 106 MSK2 72
CHK1 65 mTOR 103
CK1 82 p70S6K 61
CK2 0 PDGFRα 103
cKit 83 PDK1 96
c-RAF 102 Pim-1 58
cSRC 94 Pim-2 81
DRAK1 51 Pim-3 50
DYRK2 91 PKA 95
EGFR 31 PKBα 92
Flt1 31 PKCα 36
Flt3 83 PKD2 58
GCK 94 PRAK 65
GSK3β 147 ROCK-II 75
HIPK1 94 SAPK2a 121
HIPK2 76 SAPK3 99
HIPK3 96 SAPK4 112
KDR 62 SGK 92
Lck 113 Syk 136
  1. Residual activity is determined in the presence of 10 μM hematein under 10 μM ATP and expressed as a percentage of the control without inhibitor. Residual activities ≤ 10% are shown in bold. CDK, cyclin-dependent kinase; CHK, checkpoint kinase; CK, casein kinase; SRC, sarcoma kinase; DRAK, DAP kinase-related apoptosis-inducing protein kinase; DYRK, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase; EGFR, epidermal growth factor receptor; Flt, fms-related tyrosine kinase; GCK, gluokinase; GSK, glycogen synthase kinase; HIPK, homeodomain interacting protein kinase; KDR, kinase insert domain receptor; Lck, lymphocyte cell-specific protein-tyrosine kinase; MAPK, mitogen-activated protein kinase; MKK, mitogen-activated kinase; MSK, mitogen- and stress-activated protein kinase; mTOR, mammalian target of rapamyin; p70S6K, p70 S6 kinase; PDGFR, platelet-derived growth factor receptor; PDK, 3'-phosphoinositide-dependent kinase; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PKD, protein kinase D; PRAK, p38-regulated activated kinase; ROCK, Rho-dependent protein kinase; SRPK, serine-arginine protein kinase; SGK, serum and glucocorticoid-inducible kinase.